ACTRIMS Forum 2016

Relapsing MS Treatment Showing Efficacy in Phase 2 Extension Study, Celgene Reports at ACTRIMS 2016

Celgene CorporationĀ announced theĀ results from anĀ extension studyĀ of theĀ RADIANCE Phase 2 clinical trial evaluating ozanimod in patients with relapsing multiple sclerosis (MS). The results were also presented at the recentĀ Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016Ā in New Orleans, Louisiana. Ozanimod is a small…

MS Stem Cell Therapies Show Promise, But More Work Is Needed, Researcher Tells ACTRIMS 2016

Dr. Andrew Goodman of the University of RochesterĀ discussedĀ the latest research and perspectives on stem cell strategiesĀ forĀ people with multiple sclerosis (MS), saying in a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016Ā thatĀ such therapies, while promising,Ā are not yet ready for widespread clinical use. New therapies…

Leptomeningeal Inflammation May Offer New Treatment Targets In Progressive Forms of MS

Researchers at Johns Hopkins UniversityĀ in Baltimore presented keyĀ findings today, Feb. 19, concerningĀ the presence of contrast-enhancing lesions in later stages in the relapsing-remitting experimental autoimmune encephalitis (EAE) model. The presentation was made at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, which is ongoing through…

Results of New SPMS Study to Be Presented at ACTRIMS

At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, being held from Feb. 18ā€“20 inĀ New Orleans, LA, researchers haveĀ gathered to discuss ā€œProgressive MS: Bench to Bedside and Back,ā€ the meetingā€™s theme. Secondary progressive multiple sclerosis (SPMS) is one of four types of MS, and is…

Effects of Specific Antibodies on MS Neurodegeneration to Be Presented at ACTRIMS Forum

Researchers from the University of Tennessee Health Science CenterĀ plan toĀ present the results of a study investigating the contribution of specific antibodies to the neurodegeneration and neuronal dysfunction observed in multiple sclerosis (MS). The studyā€™s results are to be reported today, Feb. 18, at theĀ Americas Committee for Treatment and Research…

NIH Study into Progressive MS Biomarkers to Be Presented at ACTRIMS 2016

Scientists fromĀ the Neuroimmunological Diseases Unit at the National Institutes of Health (NIH) will present results ofĀ a study investigating several biomarkers that might leadĀ to a more sensitive and accurate diagnostic test of central nervous system (CNS) inflammation, aĀ keyĀ aspect ofĀ progressive multiple sclerosis (MS). The data is being reportedĀ today, Feb.18, at the…

ACTRIMS Session on MS Progression to Emphasize Continuing Treatment of Advancing Disease

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 starts today, Feb. 18, in New Orleans, Louisiana, and runs through Saturday, Feb. 20. The opening day’sĀ Session 1, titled “Emerging Concepts in MS,” placesĀ special focus onĀ cutting-edge studies onĀ the pathogenic mechanisms in multiple sclerosis (MS), new measures of…

Anavex Life Sciences to Present Preclinical Data on Lead MS Drug Candidate at ACTRIMS 2016

Anavex Life Sciences, a biopharmaceutical company focused on the development of new therapies for neurodegenerative and central nervous system (CNS) diseases, among others, recently announced the presentation of preclinical data forĀ one of its lead drug candidates, ANAVEX2-73, as a multiple sclerosis (MS) treatment. The preclinical studyā€™s lead investigator, Dr.